CLINICAL_TRIALS ClinicalTrials.gov record update

A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05747924
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:02.964235+00:00
Published At: 2026-04-24T00:00:00+00:00
Record Updated At: 2026-04-24
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["FSHD", "FSHD1", "FSHD2", "FMD", "FMD2", "Fascioscapulohumeral Muscular Dystrophy", "Fascioscapulohumeral Muscular Dystrophy Type 1", "Fascioscapulohumeral Muscular Dystrophy Type 2", "Dystrophies, Facioscapulohumeral Muscular", "Dystrophy, Facioscapulohumeral Muscular", "Facioscapulohumeral Muscular Dystrophy 1", "Facioscapulohumeral Muscular Dystrophy 2", "Facio-Scapulo-Humeral Dystrophy", "Atrophy, Facioscapulohumeral", "Atrophies, Facioscapulohumeral", "Facioscapulohumeral Atrophy", "Muscular Dystrophies", "Muscular Dystrophy, Facioscapulohumeral", "FSH Muscular Dystrophy", "Landouzy Dejerine Dystrophy", "Landouzy-Dejerine Muscular Dystrophy", "Dystrophies, Landouzy-Dejerine", "Dystrophy, Landouzy-Dejerine", "Landouzy-Dejerine Syndrome", "Muscular Dystrophy, Landouzy Dejerine", "Progressive Muscular Dystrophy", "FSH"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-24"
protocolSection.identificationModule.nctId: "NCT05747924"
protocolSection.identificationModule.officialTitle: "A Randomized, Double-blind, Placebo-controlled, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of AOC 1020 Administered Intravenously to Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Study condition terms

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.